MedTrace Logo

Randomized Phase III-Study in Stage IIIb and IV Non-Small-Cell Lung Cancer. Sequential Single-Agent vs. Double-Agent vs. Triple-Agent Therapy.

NCT00148395 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 280

Last updated 2008-04-22

No results posted yet for this study

Summary

This study wants to assess different intensive therapy sequences for the treatment of non-small-cell lung cancer.

It claims less on the efficacy of different chemotherapy combinations, than more on the comparison of different strategies of sequential single-agent, sequential double-agent or sequential triple-agent therapy.

Conditions

  • Non-Small-Cell Lung Carcinoma

Interventions

DRUG

Gemcitabine

DRUG

Navelbine

DRUG

Carboplatin

DRUG

Cisplatin

DRUG

Mitomycin

DRUG

Ifosfamide

Sponsors & Collaborators

  • Aktion Bronchialkarzinom e.V.

    lead OTHER

Principal Investigators

  • Martin Wolf, MD · Klinikum Kassel GmbH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-06-30
Completion
2008-04-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00148395 on ClinicalTrials.gov